Eaton Vance Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $565M | Buy |
4,212,972
+131,574
| +3% | +$18.9M | 0.84% | 18 |
|
|
2022
Q2 | $625M | Sell |
4,081,398
-60,469
| -1% | -$9.24M | 0.88% | 17 |
|
|
2022
Q1 | $671M | Buy |
4,141,867
+332,550
| +9% | +$48.3M | 0.77% | 20 |
|
|
2021
Q4 | $516M | Sell |
3,809,317
-50,190
| -1% | -$5.93M | 0.63% | 31 |
|
|
2021
Q3 | $412M | Buy |
3,859,507
+78,392
| +2% | +$8.96M | 0.57% | 34 |
|
|
2021
Q2 | $426M | Buy |
3,781,115
+237,044
| +7% | +$26.7M | 0.57% | 31 |
|
|
2021
Q1 | $384M | Buy |
3,544,071
+551,608
| +18% | +$59M | 0.57% | 30 |
|
|
2020
Q4 | $321M | Sell |
2,992,463
-26,672
| -0.9% | -$2.56M | 0.5% | 37 |
|
|
2020
Q3 | $264M | Buy |
3,019,135
+633,128
| +27% | +$59.6M | 0.49% | 41 |
|
|
2020
Q2 | $234M | Buy |
2,386,007
+306,146
| +15% | +$27M | 0.47% | 43 |
|
|
2020
Q1 | $158M | Sell |
2,079,861
-280,327
| -12% | -$23.9M | 0.39% | 59 |
|
|
2019
Q4 | $209M | Sell |
2,360,188
-74,651
| -3% | -$6.2M | 0.41% | 60 |
|
|
2019
Q3 | $184M | Sell |
2,434,839
-130,169
| -5% | -$8.92M | 0.4% | 64 |
|
|
2019
Q2 | $187M | Buy |
2,565,008
+39,865
| +2% | +$3.13M | 0.41% | 61 |
|
|
2019
Q1 | $204M | Sell |
2,525,143
-369,034
| -13% | -$30.2M | 0.47% | 54 |
|
|
2018
Q4 | $267M | Sell |
2,894,177
-107,349
| -4% | -$9.44M | 0.69% | 32 |
|
|
2018
Q3 | $284M | Sell |
3,001,526
-66,899
| -2% | -$6.34M | 0.63% | 35 |
|
|
2018
Q2 | $284M | Sell |
3,068,425
-3,823,911
| -55% | -$373M | 0.68% | 29 |
|
|
2018
Q1 | $652M | Buy |
6,892,336
+3,491,490
| +103% | +$384M | 0.81% | 23 |
|
|
2017
Q4 | $329M | Buy |
3,400,846
+299,221
| +10% | +$28.2M | 0.8% | 26 |
|
|
2017
Q3 | $276M | Buy |
3,101,625
+385,198
| +14% | +$29.3M | 0.71% | 32 |
|
|
2017
Q2 | $197M | Buy |
2,716,427
+68,521
| +3% | +$4.61M | 0.52% | 54 |
|
|
2017
Q1 | $173M | Sell |
2,647,906
-401,697
| -13% | -$25.3M | 0.46% | 60 |
|
|
2016
Q4 | $191M | Buy |
3,049,603
+170,855
| +6% | +$10.4M | 0.54% | 53 |
|
|
2016
Q3 | $182M | Sell |
2,878,748
-516,869
| -15% | -$33.5M | 0.52% | 53 |
|
|
2016
Q2 | $210M | Buy |
3,395,617
+1,209,779
| +55% | +$73.7M | 0.61% | 47 |
|
|
2016
Q1 | $125M | Sell |
2,185,838
-103,589
| -5% | -$5.77M | 0.38% | 77 |
|
|
2015
Q4 | $136M | Sell |
2,289,427
-3,550,113
| -61% | -$204M | 0.4% | 73 |
|
|
2015
Q3 | $318M | Buy |
5,839,540
+2,289,013
| +64% | +$149M | 0.98% | 21 |
|
|
2015
Q2 | $239M | Buy |
3,550,527
+1,331,901
| +60% | +$87M | 0.73% | 33 |
|
|
2015
Q1 | $130M | Buy |
2,218,626
+95,781
| +5% | +$5.79M | 0.39% | 81 |
|
|
2014
Q4 | $139M | Sell |
2,122,845
-41,829
| -2% | -$2.64M | 0.41% | 74 |
|
|
2014
Q3 | $125M | Sell |
2,164,674
-107,080
| -5% | -$5.94M | 0.37% | 77 |
|
|
2014
Q2 | $128M | Sell |
2,271,754
-91,698
| -4% | -$4.81M | 0.38% | 79 |
|
|
2014
Q1 | $121M | Sell |
2,363,452
-44,209
| -2% | -$2.23M | 0.36% | 84 |
|
|
2013
Q4 | $127M | Sell |
2,407,661
-267,255
| -10% | -$13.1M | 0.37% | 85 |
|
|
2013
Q3 | $120M | Sell |
2,674,916
-157,185
| -6% | -$6.97M | 0.36% | 87 |
|
|
2013
Q2 | $117M | Buy |
+2,832,101
| New | +$124M | 0.35% | 86 |
|
Other funds holding ABBV
Eaton Vance Management's ABBV Position: Q3 2022 in Review
Eaton Vance Management increased its AbbVie (ABBV) stake by 3.2% in Q3 2022, buying an estimated $18.9M and bringing the position to 4,212,972 shares worth $565M. The position accounts for 0.84% of the portfolio, ranked #18.
Eaton Vance Management first reported a position in ABBV in Q2 2013 and has held it in 38 quarters since. The position peaked at $671M in Q1 2022. 2,968 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.
- Eaton Vance Management held 4,212,972 shares of AbbVie worth $565M as of Q3 2022.
- Eaton Vance Management bought 131,574 AbbVie shares in Q3 2022, an estimated $18.9M.
- AbbVie made up 0.84% of Eaton Vance Management's portfolio in Q3 2022, its #18 holding.
- Eaton Vance Management first reported a position in AbbVie in Q2 2013 and has held it in 38 quarters since.
- Eaton Vance Management's AbbVie position peaked at $671M in Q1 2022.
- 2,968 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.
Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.